|  |  |
| --- | --- |
| **PROGRAM** | |
| **Wednesday February 28th** | |
| **8:00** | **Registration** |
|  |  |
| **8:45-9:00** | **Welcome and Introduction**  **Prof. Annemieke Madder** |
|  |  |
| **9:15** | ***Session 1***  ***Peptide materials and delivery***  **Chairman: Prof. José Martins** |
|  |  |
| **9:00-9:45**  **Plenary 1** | **Prof. M. Aguilar,** ***Department of Biochemistry & Molecular Biology,***  ***Monash University, Australia***  ***Modular Design of Peptide-Based Materials for Tissue Regeneration*** |
| **9:45-10:05**  **Oral 1** | **M. Mannes**, *Research Group of Organic Chemistry, Vrije Universiteit Brussel, Belgium*  ***Injectable peptide hydrogels for controlled drug release*** |
| **10:05-10:25**  **Oral 2** | **J. Martin**, *Institute of Biomolecules Max Mousseron (IBMM), Montpellier, France*  ***Direct synthesis of peptide-modified silicone. A new way for bioactive materials*** |
| **10:25-10:55** | **Coffee Break** |
| **10:55** | ***Session 2***  ***Peptide discovery and medicinal chemistry***  **Chairman: Prof. Steven Ballet** |
|  |  |
| **10:55-11:40**  **Plenary 2** | **Dr. E. Valeur,** *Medicinal Chemistry, Cardiovascular and Metabolic Diseases, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden*  **Drugging the ‘undruggable’: New Peptide-based Modalities in cardiovascular and metabolic diseases** |
| **11:40-12:00**  **Oral 3** | **M. Amoura**, *Laboratoire des Biomolécules, UMR 7203, Université Pierre et Marie Curie-Paris 6, CNRS, ENS, Paris, France*  ***Design and study of new cyclic cell-penetrating peptides*** |
| **12:00-12:20**  **Oral 4** | **Dr. M. Sanchez-Navarro**, *Institute for Research in Biomedicine (IRB), Barcelona, Spain*  ***Modifying Fraxatin with blood-brain barrier peptide shuttles: paving the way towards protein replacement therapy*** |
| **12:20-12:40**  **Oral 5** | **V. Ornelis ,** *Organic and Biomimetic Chemistry Research Group, Ghent University, Belgium*  ***Detection and selective trapping of the Mycotoxins Beauvericin and Enniatins: a synthesis driven endeavour*** |
|  |  |
| **12:40-13:45** | **Lunch Break and Poster Session 1 (*odd numbers*)** |

|  |  |
| --- | --- |
| **13:45** | ***Session 2 Continued***  ***Peptide discovery and medicinal chemistry***  **Chairman: Prof. Em. Dirk Tourwé** |
|  |  |
| **13:45-14:30**  **Plenary 3** | **Prof. K. Stromgaard**, *Center for Biopharmaceuticals, Department of Drug Design and Pharmacology, University of Copenhagen*  *****Targeting Protein-Protein Interactions of Receptor Complexes***** |
| **14:30-14:50**  **Oral 6** | **Dr. A. Knuhtsen**, *School of Chemistry, University of Glasgow, United Kingdom*  ***Does secondary structure determine biological activity? A study of µ-Conotoxin KIIIA mimetics*** |
| **14:50-15:10**  **Oral 7** | **T.M. Vishwanatha,** *Centre de Biophysique Moléculaire, CNRS, UPR 4301, Orléans, France.*  *Rational design of kisspeptin analogs for the control of reproduction* |
| **15:10-15:30**  **Oral 8** | **Ishwar Singh**, *School of Pharmacy,**University of Lincoln, United Kingdom*  ***Teixobactin and its simplified analogues, a new hope in antibiotic discovery*** |
| **15:30-16:00** | **Coffee Break** |
| **16:00** | ***Session 3***  ***Peptide biology and pharmacology***  **Chairman: Prof. Annemieke Madder** |
| **16:00-16:20**  **Oral 9** | **C. Raaymakers,** *Amphibian Evolution Lab, Biology Department, Vrije Universiteit Brussel, and Department of Pathology, Bacteriology, and Avian diseases, Faculty of Veterinary Medicine, Ghent University, Belgium*  ***Antimicrobial peptides in frog poison constitute a molecular toxin delivery system against predators*** |
| **16:20-16:40**  **Oral 10** | **C. Struyfs,** *Centre of Microbial and Plant Genetics, KU Leuven, Leuven and*  *Department of Plant Systems Biology, VIB, Ghent, Belgium*  ***Study of the antifungal mode of action of plant defensins using single cell analysis*** |
| **16:40-17:00**  **Oral 11** | **Prof. A.M. Lambeir**, *Laboratory of Medical Biochemistry, University of Antwerp*  ***Exploring enzymatic mechanisms of proline specific peptidases using ITC*** |
| **17:00-17:20**  **Oral 12** | **Prof. N.R. Thomas**, *School of Chemistry, Centre for Biomoleular Sciences, University of Nottingham*  ***‘Clickable’ Recombinant Spider Silk and its Healthcare Applications*** |
|  |  |
| **17:30** | **Reception** |

|  |  |
| --- | --- |
|  | |
| **Thursday March 1st** | |
| **8:15** | **Registration** |
|
| **8:30** | ***Session 4***  ***Peptide******structure and function***  **Chairman: Dr. Mimoun Ayoub** |
|  |  |
| **8:30-9:15**  **Plenary 4** | **Prof. C. P.R. Hackenberger, *Humboldt Universität zu Berlin; Leibniz-Institut für Molekulare Pharmakologie (FMP)***  **The power of chemoselectivity: functional peptide and protein-conjugates for proteomic and pharmaceutical research** |
| **09:15-9:35**  **Oral 13** | **E. Ottoy**, *NMR and Structure Analysis Unit, Faculty of Science, Ghent University*  *Full conformational characterization of novel fluorinated prolines* |
| **9:35-9:55**  **Oral 14** | **V. Declerck**, *CP3A Organic Synthesis Group, ICMMO, Université Paris–Sud, Université Paris Saclay, Orsay, France*  ***C to N replacement in cyclic β-amino acids: a strategic tool for controlling helicity of β-peptides*** |
| **9:55-10:15**  **Oral 15**  **10:15-10:35**  **Oral 16** | **N. Geudens**, *NMR and Structure Analysis Unit, Faculty of Science, Ghent University*  *Form and function: structural variations of natural cyclic lipopeptides*  **M. Silk,** *Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Melbourne, Australia*  ***The direct synthesis of cyclic D/L peptide nanotubes*** |
| **10:35-11:05** | **Coffee Break** |
| **11:05** | ***Session 5***  ***Peptide******synthesis and technology***  **Chairman: Prof. Gilles Subra** |
|  |  |
| **11.05-11:25**  **Oral 17** | **Dr. D. Ormerod**, *Separation and Conversion Technology, Flemish Institute for Technological Research (VITO NV), Belgium*  ***The application of membrane technology to peptide synthesis*** |
| **11:25-11:45**  **Oral 18** | **M. Schmidt,** *EnzyPep B.V., Brightlands Campus, Geleen and Van’t Hoff Institute of*  *Molecular Sciences, University of Amsterdam, The Netherlands.*  ***Omniligase-1: a powerful tool for peptide head-to-tail cyclization*** |
| **11:45-12:05**  **Oral 19** | **N. J. Mitchell,** *School of Chemistry, University of Nottingham, United Kingdom*  ***Accelerated protein synthesis via one-pot ligation-deselenization chemistry*** |
| **12:05-12:25**  **Oral 20** | **Prof. I. Dijkgraaf**, *Department of Biochemistry, Maastricht University, Maastricht, The Netherlands*  ***Targeting cardiovascular disease using a tick-derived protein*** |
|  |  |
| **12:25-13:30** | **Lunch Break and Poster Session 2 (*even numbers*)** |

|  |  |  |
| --- | --- | --- |
|  | | ***Session 5 Continued***  ***Peptide******synthesis and technology***  **Chairman: Dr. Vincent Aucagne** |
| **13:30-14:15**  **Plenary 5** | | **Prof. W.D. Lubell**, *Department of Chemistry, Université de Montréal, Montréal, Quebec, Canada* ***Coming full circle from turn mimicry to cyclic peptidomimetics*** |
| **14:15-14:35**  **Oral 21** | | **Prof. D.V. Filippov,** *Leiden Institute of Chemistry, Leiden University, Leiden, The Netherlands*  ***Chemical approaches to mono-ADP-ribosylation of amino acids, peptides and proteins*** |
| **14:35-14:55**  **Oral 22** | | **Prof. S. Mangelinckx**, *Department of Green Chemistry and Technology, Ghent University, Ghent*  ***Cyclization of N-(3-hydroxyacyl)amino acids to 1,4-oxazepane-2,5-diones*** |
| **14:55-15:15**  **Oral 23** | | **S. Verlinden**, *Research Group of Organic Chemistry, Vrije Universiteit Brussel, Belgium*  ***The 1,3-diyne linker as a tunable tool for peptide secondary structure stabilization*** |
| **15:15-15:35**  **Oral 24** | | **Dr. G. Chaume**, Laboratoire de Chimie Biologique (LCB), Université de Cergy-Pontoise, Cergy-Pontoise, France  ***Homochiral verus heterochiral trifluoromethylated pseudoproline containing dipeptides: a powerful tool to switch the prolyl-amide bond conformation*** |
|  | |  |
| **15:35-15:50** | **Concluding Remarks**  **Prof. Annemieke Madder** | |